BUY Benidipine hydrochloride

Both L-type (Ca_V1) and T-type (Ca_V3) voltage gated Ca²⁺ channels are large (~ 0.5 MDa), transmembrane proteins which control the cellular influx of Ca²⁺ in response to electrical stimulus; while Ca_V1s require a strong depolarization (~ +40 mV) to perform, a much weaker pulse (~ -40 mV) is sufficient to activate Ca_V3s.
Ca²⁺ channel blockers (CCBs) are a diverse class of pharmaceutical agents, usually targeted at Ca_V1s, of which dihydropyridines (DHPs) constitute a major subgroup. Inhibitors of Ca²⁺-mediated smooth muscle contractions, CCBs produce vasodilation, thus therapeutically managing hypertension and coronary heart disease. Additionally, benidipine is known to be an endothelium protectant as well as an antioxidant.
A DHP derivative, benidipine hydrochloride acts as a triple-channel (Ca_V1, Ca_V2 and Ca_V3) blocker and is characterized by slow onset of action and high affinity for the binding sites of its target channels; with a Ki value of 0.08-0.13 nmol/L benidipine's cell-membrane association is considerably greater than other DHPs, and a dissociation rate which is 9 times slower than that of nifedipine makes it distinguishably long-lasting.